Literature DB >> 26567981

Cardiac Syndrome X: Update.

Shilpa Agrawal1, Puja K Mehta2, C Noel Bairey Merz3.   

Abstract

Cardiac Syndrome X (CSX), characterized by angina-like chest discomfort, ST segment depression during exercise, and normal epicardial coronary arteries at angiography, is highly prevalent in women. CSX is not benign, and linked to adverse cardiovascular outcomes and a poor quality of life. Coronary microvascular and endothelial dysfunction and abnormal cardiac nociception have been implicated in the pathogenesis of CSX. Treatment includes life-style modification, anti-anginal, anti-atherosclerotic, and anti-ischemic medications. Non-pharmacological options include cognitive behavioral therapy, enhanced external counterpulsation, neurostimulation, and stellate ganglionectomy. Studies have shown the efficacy of individual treatments but guidelines outlining the best course of therapy are lacking.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angina; Cardiac syndrome X; Ischemia; Microvascular endothelial dysfunction; Myocardial hypersensitivity

Year:  2016        PMID: 26567981     DOI: 10.1016/j.hfc.2015.08.012

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  8 in total

1.  Ultrasound-Guided Percutaneous Cervical and Upper Thoracic Sympathetic Chain Neuromodulation for Upper Extremity Complex Regional Pain Syndrome.

Authors:  Samer Narouze; Dmitri Souzdalnitski
Journal:  Ochsner J       Date:  2017

2.  Investigation of MTHFR gene C677T polymorphism in cardiac syndrome X patients.

Authors:  Cemre Kandaz; Burak Önal; Deniz Özen; Bülent Demir; A Gökhan Akkan; Sibel Özyazgan
Journal:  J Clin Lab Anal       Date:  2017-05-08       Impact factor: 2.352

3.  Heart rate reserve during pharmacological stress is a significant negative predictor of impaired coronary flow reserve in women.

Authors:  Ahmed Haider; Susan Bengs; Monika Maredziak; Michael Messerli; Michael Fiechter; Andreas A Giannopoulos; Valerie Treyer; Moritz Schwyzer; Christel Hermann Kamani; Dimitri Patriki; Elia von Felten; Dominik C Benz; Tobias A Fuchs; Christoph Gräni; Aju P Pazhenkottil; Philipp A Kaufmann; Ronny R Buechel; Catherine Gebhard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-16       Impact factor: 9.236

Review 4.  Physiological Consequences of Coronary Arteriolar Dysfunction and Its Influence on Cardiovascular Disease.

Authors:  Hassan Allaqaband; David D Gutterman; Andrew O Kadlec
Journal:  Physiology (Bethesda)       Date:  2018-09-01

Review 5.  Endothelial Dysfunction and Coronary Vasoreactivity - A Review of the History, Physiology, Diagnostic Techniques, and Clinical Relevance.

Authors:  Tharusha Gunawardena; Ioannis Merinopoulos; Upul Wickramarachchi; Vassilios Vassiliou; Simon Eccleshall
Journal:  Curr Cardiol Rev       Date:  2021

6.  Increased levels of angiogenic factors in microvascular angina.

Authors:  Elmira Roshani Asl; Yousef Rasmi; Mohammad-Hasan Khadem-Ansari; MirHossein Seyed-Mohammadzad; Alireza Rostamzadeh; Fereshteh Ghaffari; Narmin Mokarizadeh
Journal:  Med Pharm Rep       Date:  2019-01-15

7.  Nebivolol for improving endothelial dysfunction in cardiac syndrome-x; Is it ready for clinical use?

Authors:  Alireza Fatahian
Journal:  ARYA Atheroscler       Date:  2019-11

8.  The effect of nicorandil in patients with cardiac syndrome X: A meta-analysis of randomized controlled trials.

Authors:  Qiulei Jia; Shuqing Shi; Guozhen Yuan; Jingjing Shi; Shuai Shi; Yi Wei; Yuanhui Hu
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.